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Abstract
Introduction: The adhesion protein junctional adhesion molecule-A (JAM-A) regulates epithelial cell morphology
and migration, and its over-expression has recently been linked with increased risk of metastasis in breast cancer
patients. As cell migration is an early requirement for tumor metastasis, we sought to identify the JAM-A signalling
events regulating migration in breast cancer cells.
Methods: MCF7 breast cancer cells (which express high endogenous levels of JAM-A) and primary cultures from
breast cancer patients were used for this study. JAM-A was knocked down in MCF7 cells using siRNA to determine
the consequences for cell adhesion, cell migration and the protein expression of various integrin subunits. As we
had previously demonstrated a link between the expression of JAM-A and b1-integrin, we examined activation of
the b1-integrin regulator Rap1 GTPase in response to JAM-A knockdown or functional antagonism. To test whether
JAM-A, Rap1 and b1-integrin lie in a linear pathway, we tested functional inhibitors of all three proteins separately
or together in migration assays. Finally we performed immunoprecipitations in MCF7 cells and primary breast cells
to determine the binding partners connecting JAM-A to Rap1 activation.
Results: JAM-A knockdown in MCF7 breast cancer cells reduced adhesion to, and migration through, the b1-
integrin substrate fibronectin. This was accompanied by reduced protein expression of b1-integrin and its binding
partners aV- and a5-integrin. Rap1 activity was reduced in response to JAM-A knockdown or inhibition, and
pharmacological inhibition of Rap1 reduced MCF7 cell migration. No additive anti-migratory effect was observed in
response to simultaneous inhibition of JAM-A, Rap1 and b1-integrin, suggesting that they lie in a linear migratory
pathway. Finally, in an attempt to elucidate the binding partners putatively linking JAM-A to Rap1 activation, we
have demonstrated the formation of a complex between JAM-A, AF-6 and the Rap1 activator PDZ-GEF2 in MCF7
cells and in primary cultures from breast cancer patients.
Conclusions: Our findings provide compelling evidence of a novel role for JAM-A in driving breast cancer cell
migration via activation of Rap1 GTPase and b1-integrin. We speculate that JAM-A over-expression in some breast
cancer patients may represent a novel therapeutic target to reduce the likelihood of metastasis.
Introduction
Breast cancer accounts for approximately 30% of all
female cancers diagnosed in the European Union and is
the leading cause of female cancer deaths. Over 85,000
women (many in their reproductive and economically
productive years) succumbed to the disease in 2006 [1].
Although there have been substantial improvements in
breast cancer treatment, targeted adjuvant therapies are
restricted to treating those patients whose tumor cells
express high levels of the few targetable breast cancer
molecular markers, namely the estrogen and HER2
(human epidermal growth factor receptor 2) receptors.
It is therefore clear that further improvements are
needed in the molecular understanding, diagnosis, and
treatment of breast cancer.
Most breast cancers originate in the epithelial cells lin-
ing breast ducts. Epithelial cell polarity in normal ducts is
maintained via intercellular multiprotein adhesion
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cation between neighboring cells. Loss of epithelial polar-
ity and consequent disruptions in tissue architecture, a
hallmark of de-differentiation, are early features of breast
cancer and other malignancies [2]. Emerging evidence
points toward an important role for proteins of the inter-
cellular tight junction (TJ) complex in mediating tumori-
genesis. To date, several TJ proteins have been shown to
be dysregulated in breast carcinoma, with claudins-3 and
-4 highly upregulated [3] and claudin-7 downregulated in
in situ and invasive ductal carcinomas [4]. Furthermore,
loss of the TJ-associated protein ZO-1 (zona occludens-1)
in breast cancer correlates with both poor prognosis [5]
and increased expression of proteinases important for
tumor invasion [6]. Interestingly, adhesion/polarity pro-
teins have recently been shown to be targeted by onco-
genes (such as ERBB2 [7] and MYC [8]), resulting in the
disruption of tissue organization often observed during
cancer development. Together, these studies provide
strong evidence that adhesion proteins may act as key reg-
ulators of breast cancer initiation and progression.
The junctional adhesion molecule (JAM) family of TJ
proteins has important functions in numerous cellular
adhesive processes, including intercellular junction
assembly and cell polarity [9], cell morphology [10], pla-
telet activation [11], and leukocyte migration [12].
Pathophysiologically, JAM-A has been linked to various
inflammatory disorders [13-15] and, more recently,
some cancers [16,17]. However, discordance exists
regarding the specific role of JAM-A in breast cancer
[18,19]. Our previous investigations into the role of
JAM-A in breast cancer had analyzed levels of JAM-A
expression in two cohorts of patients with invasive
breast cancer. We demonstrated a novel and significant
association between JAM-A overexpression in breast tis-
sue and poor prognosis for patients with breast cancer
[19]. Notably, patients whose tumors had high JAM-A
expression levels were significantly more likely to
develop metastasis. Given that migratory capacity is cru-
cial for tumor cell dissemination and that JAM-A has
established functions in leukocyte migration [12], we
sought to determine the contribution of JAM-A to
breast cancer cell migration in vitro. Our study has
demonstrated that, likely owing to a concomitant reduc-
tion in expression of the migratory protein b1-integrin,
antagonism or knockdown of JAM-A in MCF7 human
breast cancer epithelial cells significantly decreases cell
migration [20]. b1-integrin has been strongly linked
with murine breast proliferation [21] and the formation
of metastases in mouse models of breast cancer [22].
Accordingly, results from our [19] and other [23] tissue
microarray studies have shown an association between
high b1-integrin expression levels and poor prognosis in
patients with breast cancer.
In this study, we further investigated the JAM-A sig-
nalling events that regulate b1-integrin-dependent
migratory events in breast cancer cells. We demon-
strated that reductions in cell migration following JAM-
A functional antagonism or short interfering RNA
(siRNA)-mediated gene knockdown are exerted via
downstream effects on the activity of Rap GTPase1, a
known activator of b1-integrins [24] and a regulator of
breast tumorigenesis [25]. Furthermore, we present data
suggesting that JAM-A may activate Rap1 indirectly
through associations with downstream signalling pro-
teins AF-6 and the guanine exchange factor, PDZ-GEF2.
Finally, using ex vivo immunoprecipitation (IP) strategies
in primary cultures generated from patients with breast
cancer, we demonstrate that the JAM-A signalling com-
plexes identified in vitro in MCF7 cells also exist in tis-
sues of patients with breast cancer. Given both the
regulatory influence of JAM-A on breast cancer cell
migration in vitro and its link with metastasis in patient
tissue samples [19], our studies suggest a role for JAM-
A as a potentially important therapeutic target for the
development of future breast cancer therapies.
Materials and methods
Cell culture
The MCF7 breast cancer cell line was obtained from the
European Collection of Cell Cultures through Sigma-
Aldrich (Poole, UK) and maintained in minimum essen-
tial medium (Sigma-Aldrich) supplemented with 10%
fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 2
mM L-glutamine, 50 U/mL penicillin, 50 μg/mL strepto-
mycin (Invitrogen Corporation, Carlsbad, CA, USA), and
1% non-essential amino acids (Sigma-Aldrich). Cells
were maintained at 37°C in humidified air with 5% CO2.
Primary culture generation
Human breast tissue samples from lumpectomy or mas-
tectomy patients were gathered with informed consent
in protocols approved by the Beaumont Hospital medi-
cal ethics (research) committee and were used to gener-
ate mammary epithelial primary cell cultures with minor
modifications from published methods [26]. In brief, tis-
sue biopsies from within the tumor (T) and from histo-
pathologically normal non-tumor margins (N) were
incubated in penicillin/streptomycin/neomycin (Invitro-
gen Corporation); minced in Dulbecco’s modified Eagle’s
medium/F12 (Sigma-Aldrich) containing penicillin/
streptomycin/neomycin, 10% FBS, 10 μg/mL insulin,
5 μg/mL fungizone, 100 U/mL hyaluronidase 1-S, and
200 U/mL collagenase (Sigma-Aldrich); and agitated for
2 hours at 37°C. Cells were pelleted and washed before
being cultured in mammary epithelial growth medium
(Lonza) at 37°C with 5% CO2. Trypsin/ethylenediamine-
tetraacetic acid and soybean trypsin inhibitor were used
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one passage to generate enough material for IP assays
and one or two passages for protein isolation. Only
patient-matched primary cultures were used (Table 1).
siRNA-mediated gene-expression knockdown
JAM-A siRNAs were transfected into MCF7 breast can-
cer cells using the N-TER nanoparticle siRNA transfec-
tion system (Sigma-Aldrich). In brief, cells (1.5 × 10
6
cells/10-cm dish) were seeded 16 hours prior to trans-
fection. Cells were washed in phosphate-buffered saline
(PBS) and transfected with nanoparticles containing
75 nM final concentration of JAM-A siRNAs, negative con-
trol siRNA, or mock (N-TER reagent only) in minimum
essential medium. Assays were performed after transfection
for 48 hours at 37°C with 5% CO2. Two alternative JAM-A
siRNAs were used for all experiments. Representative
results from a single siRNA are shown for clarity.
Antibodies/inhibitors
All antibodies used for Western blot and immunofluores-
cence analyses were obtained from commercial sources:
rabbit polyclonal anti-JAM-A (Zymed Laboratories Inc.,
now part of Invitrogen Corporation), MAb13 rat anti-b1
integrin (BD Biosciences, San Jose, CA, USA), rabbit anti-
b2, rabbit anti-b3, rabbit anti-b4, rabbit anti-b5, rabbit
anti-aV, rabbit anti-a4, rabbit anti-a5 integrins (Cell Sig-
naling Technology, Danvers, MA, USA), rabbit anti-actin
(Abcam, Cambridge, UK), rabbit anti-Rap1 (Millipore Cor-
poration, Billerica, MA, USA), rabbit anti-AF-6 (Invitrogen
Corporation), mouse anti-PDZGEF2 (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA), and mouse J.10.4 inhi-
bitory anti-JAM-A (Santa Cruz Biotechnology, Inc.).
Horseradish peroxidase (HRP)-conjugated secondary anti-
bodies were anti-mouse and anti-rat (Sigma-Aldrich) or
anti-rabbit (Cell Signaling Technology). IgG isotype con-
trol antibodies were mouse, rabbit, and rat (Sigma-
Aldrich). The Rap1 pharmacological inhibitor was GGTI-
298 (Calbiochem/Merck, Darmstadt, Germany).
Adhesion assay
Cell adhesion strips coated with fibronectin (which
binds aVb1a n da5b1i n t e g r i n s )o rb o v i n es e r u m
albumin (BSA)-control substrate (Millipore Corporation)
were rehydrated in 96-well plates with PBS for 30 min-
utes at room temperature. Cells (1 × 10
5/well) were
a d d e da n di n c u b a t e df o r2h o u r sa t3 7 ° Ca n d5 %C O 2,
washed in PBS, stained with 0.2% crystal violet (Sigma-
Aldrich) in 10% ethanol for 5 minutes at room tempera-
ture, and rinsed in PBS. Cell-bound stain was solubilized
by gently shaking with solubilization buffer (1:1, 0.1 M
NaH2PO4:50% ethanol) for 5 minutes. Absorbance was
measured at 560 nm on a microplate reader. Results
from three independent experiments with three repli-
cates per experiment were pooled.
Migration assays
Transwell migration assays were conducted on MCF7
cells following transient JAM-A gene-expression knock-
down. Transwell chambers (8 μM pore) were coated
with 10 μg/mL fibronectin (Sigma-Aldrich) overnight at
4°C, washed in PBS, and rehydrated with serum-free
media for 30 minutes at 37°C. Media were removed and
cells (1 × 10
5/chamber) were added to upper chambers
with 15% FBS in lower chambers as a chemoattractant.
Chambers were incubated for 3 hours at 37°C and 5%
CO2. Migrated cells on the underside of the filter were
fixed in 10% ethanol for 20 minutes prior to staining
with 4,6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich) for 10 minutes at room temperature. Mem-
branes were mounted on glass slides and cells were
enumerated using Cell B software (Olympus, Tokyo,
Japan) to analyze multiple fluorescent micrographs.
Results from three independent experiments with three
replicates per experiment were pooled.
Scratch-wound migration assays were conducted on
wild-type MCF7 cells after treatment with inhibitors.
Confluent cell monolayers in 24-well plates were prein-
cubated for 2 hours with 5 μg/mL mouse anti-JAM-A
J.10.4 antibody, 5 μg/mL MAb13 anti-b1 integrin anti-
body, 10 μM Rap1 inhibitor GGTI-298, appropriate
isotype-control IgG, or dimethyl sulphoxide (Sigma-
Aldrich) vehicle control. A scratch wound was made
using a pipette tip. Media were replaced and wounds
were photographed at 0, 2, and 6 hours. Scion Image
software (Scion Corporation Ltd., Frederick, MD, USA)
was used to measure closure of the wound over time by
averaging six individual measurements of wound size for
each wound at each timepoint. Results from three inde-
pendent experiments with three replicates per experi-
ment were pooled.
Rap1 activity assay
Adherent cells were washed in Tris-buffered saline and
then scraped and dounced in 1 mL of Rap1 activation
lysis buffer containing 50 mM Tris-HCl, 0.5 M NaCl,
1% NP40, 2.5 mM MgCl2, and 15% glycerol (Millipore
Table 1 Pathological parameters of human breast tissue
primary cultures
Tissue Age, years Diagnosis Grade ER PR HER2
1T, 1N 53 IDC 2 + + -
2T, 2N 32 DCIS NA + + NA
3T, 3N 42 IDC 3 - - -
The estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor-2 (HER2) status of each patient’s tissue culture was
derived directly from the histopathology report on each case. DCIS, ductal
carcinoma in situ; IDC, invasive ductal carcinoma; NA, not available.
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tors (Sigma-Aldrich). Lysates were incubated with 30 μg
of Ral GDS-RBD (Rap-binding domain) agarose slurry
(Millipore Corporation) for 45 minutes at 4°C. Beads
were pelleted and washed in lysis buffer. Bound proteins
were recovered by boiling at 95°C for 5 minutes in
40 μL of 2X sample buffer. Each immunoblot depicted
is representative of three independent experiments, and
densitometry was conducted on triplicate experiments.
Densitometric data were used to determine the average
active-to-total Rap1 protein expression over triplicate
experiments.
Western blotting
Cultured cells were washed in 10 mL of PBS, scraped,
and dounced in Relax lysis buffer containing 100 mM
KCl, 3 mM NaCl, 3.5 mM MgCl2, 10 mM HEPES pH 7.4,
and 1% Triton-X100 as well as protease and phosphatase
inhibitor cocktails (Sigma-Aldrich). Protein samples were
separated by SDS-PAGE under reducing conditions by
using Tris-glycine running buffer. After electrophoresis,
proteins were transferred to nitrocellulose membranes
(Optitran; Sigma-Aldrich). Membranes were blocked in
5% milk for 1 hour. Protein expression was detected by
using primary antibodies incubated overnight at 4°C.
Membranes were washed and incubated for 1 hour with
HRP-conjugated secondary antibodies. Antigen-antibody
complexes were detected by using Western Lightning
Enhanced Chemiluminescence reagent (PerkinElmer,
Waltham, MA, USA). Each immunoblot depicted is
representative of three independent experiments, and
densitometry was conducted on triplicate experiments.
Immunoprecipitation
Protein extraction was conducted as above. Equal pro-
tein concentrations from control siRNA, JAM-A siRNA,
and mock-transfected cells were subjected to JAM-A IP.
Preclear was conducted via rotation of protein lysates
for 1 hour at 4°C with protein G-sepharose beads (GE
Healthcare, Chalfont St.Giles, Bucks, UK). IP antibodies
(J.10.4 anti-JAM-A antibody or isotype control mouse
IgG; 4 μg/mL) were rotated for 1 hour at 4°C. Bound
antibody was retrieved by rotation with protein G-
sepharose beads for 3 hours at 4°C. Beads were washed
in Relax lysis buffer, and bound proteins were recovered
by boiling at 95°C for 5 minutes in 40 μL of 2X sample
buffer. Western blotting was performed as above for
JAM-A, AF-6, PDZ-GEF2, Rap1, and b1-integrin. Each
IP and associated immunoblot was conducted three
times for cell lines and once each per primary culture.
Statistical analysis
Averaged data from triplicate adhesion, transwell migra-
tion, and Western blot experiments were used to
generate bar graphs depicting average values ± standard
deviations, with paired Student t tests used to measure
significance. For scratch-wound migration assays ± inhi-
bitors, linear regression analysis was used to calculate
any differences between treatments and controls.
Results
JAM-A knockdown decreases integrin-mediated cancer
cell adhesion and migration
Our previous study reported that high JAM-A expres-
sion levels in breast tissues from patients with invasive
breast cancer correlated with reduced metastasis-free
survival [19]. We and others have demonstrated that,
likely owing to reductions in b1-integrin protein, knock-
down of JAM-A gene expression in epithelial cells
results in decreased collective cell migration [19,27,28]
(Supplementary Figure S1A in Additional file 1). Indeed,
integrins perform key roles at several key steps required
for cell migration: adhesion assembly, disassembly, and
turnover [29,30]. Taken together, our results to date
suggest a role for JAM-A in promoting breast cancer
cell migration through a b1-integrin-dependent pathway.
To investigate this hypothesis, we used the MCF7 breast
cancer cell line, which expresses high endogenous levels
of JAM-A and b1-integrin. JAM-A protein levels were
knocked down in these cells using a nanoparticle deliv-
ery system to transiently transfect cells with siRNA tar-
geting JAM-A. Transiently-tranfected cells were
analyzed after 48 hours for JAM-A knockdown at the
protein level. JAM-A siRNA transfected cells displayed a
90% reduction in JAM-A protein expression (Figure 1a).
Similar effects were observed with a second JAM-A
siRNA construct (Supplementary Figure S1B in Addi-
tional file 1).
To investigate the link between JAM-A, b1-integrin, and
cell migration, the ability of transfected cells to adhere to
and migrate across a fibronectin substrate was analyzed
(Figure 1b, c). Fibronectin binds multiple b1-integrin
proteins through an RGD domain [31] and thus was used
to facilitate analysis of the effects of JAM-A knockdown.
First, transfected cells were allowed to adhere to fibro-
nectin-coated transwell supports prior to cell staining
and absorbance measurement. JAM-A knockdown cells
showed an approximate 40% reduction in adhesion to
fibronectin (Figure 1b) (P = 0.02) but not to control
transwells coated with BSA (data not shown). Next,
transfected cells were allowed to migrate across fibronec-
tin-coated supports with 8-μm pores prior to fluorescent
staining and enumeration. Here, in addition to showing a
reduction in collective cell migration demonstrated in
previous reports [19,27,28], JAM-A knockdown cells
showed an approximate 50% reduction in individual cell
motility in these matrix-specific transwell migration
assays (Figure 1c) (P = 0.01), further underlining the
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cer cell migration. However, JAM-A antagonism did not
reduce invasion of MCF7 cells across Matrigel-coated fil-
ters in classic invasion assays (Supplementary Figure S2C
in Additional file 2), owing to the fact that MCF7 cells
are virtually non-invasive in this model (Supplementary
Figure S2A in Additional file 2).
JAM-A regulates b1-integrins and Rap1 GTPase in breast
cancer cells
We and others have previously reported that JAM-A
knockdown induces a concomitant reduction in b1-integ-
rin in epithelial cells [10,19,27]. To probe whether this
was a specific effect of JAM-A knockdown on b1-integrin
in breast cancer cells, the expression of several integrin
subunit proteins was analyzed following JAM-A knock-
down in MCF7 breast cancer cells. Total protein isolates
were prepared from MCF7 cells transfected with either
JAM-A siRNA or control siRNA, and the protein expres-
sion levels of a panel of alpha- and beta-subunit integrins
were assessed by Western blot analysis (Figure 2a, b). As
previously stated, JAM-A siRNA transfectants achieved a
greater than 90% reduction in JAM-A protein expression
in comparison with control siRNA transfection. No
change in the expression of b3-, b4-, or b5-integrins was
observed upon JAM-A knockdown, as evidenced by den-
sitometric analysis of triplicate immunoblots (Figure 2b).
Expression of a4-integrin was not detected in MCF7
cells. Similar to previous studies [10,19,27], a 50% reduc-
tion in the expression of b1-integrin was observed upon
transient JAM-A knockdown. Furthermore, reductions of
approximately 30% and 60%, respectively, were observed
for protein expression levels of aV- and a5-integrin sub-
units, both of which have been widely reported to com-
plex with b1-integrin to form functioning fibronectin
receptors [32]. These results further suggest that JAM-A
exerts specific effects on b1-integrin heterodimers.
We next sought to investigate the signalling events
connecting JAM-A engagement at the cell-cell interface
to b1-integrin function at the cell-matrix interface. Given
the spatial separation of these proteins, we hypothesized
that their physical association was unlikely. To test this,
JAM-A IPs were conducted on protein isolates from
MCF7 cells transfected with JAM-A or control siRNA
(Figure 2c). A reduction of b1-integrin total protein
expression was confirmed in input samples of equal pro-
tein concentration. However, no bands were observed in
JAM-A immunoprecipitated lanes immunoblotted for
b1-integrin, confirming an absence of physical associa-
tion between JAM-A and b1-integrin. We therefore con-
cluded that other signalling proteins must be responsible
for linking b1-integrin function to JAM-A.
One candidate protein, the integrin activator Rap1
GTPase [33], has been shown to regulate tissue polarity,
lumen formation, and invasive potential in human breast
epithelial cells [25]. We therefore investigated whether
JAM-A knockdown using siRNA or functional inhibition
using JAM-A inhibitory antibody altered Rap1 expres-
sion and activity (Figure 2d). Western blot analyses of
Figure 1 JAM-A knockdown reduces breast cancer cell
adhesion and migration. (a) Transfection of MCF7 breast cancer
cells with short interfering RNA (siRNA) targeting JAM-A reduces
JAM-A protein expression. (b) Adhesion of MCF7 cells transfected
with JAM-A siRNA to a fibronectin substrate was reduced relative to
that induced under control conditions. (c) Individual cell migration
of MCF7 cells transfected with JAM-A siRNA or control siRNA MCF7
cells across fibronectin-coated, 8-μm pore filters was reduced
relative to control conditions. Images show DAPI (4’-6-diamidino-2-
phenylindole)-stained migrated cells on transwell filters. Error bars
refer to standard deviation of pooled triplicate experiments. JAM-A,
junctional adhesion molecule-A.
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panel of alpha- and beta-subunit integrins was conducted on MCF7 cell lines transfected with control short interfering RNA (siRNA) or JAM-A-
siRNA. Assessment of actin expression was performed to control for protein loading. (b) Densitometry analysis of triplicate Western blot
experiments showing relative protein expression of alpha- and beta-subunit integrins. Error bars refer to standard deviation of triplicate
experiments. (c) b1-integrin Western blot analysis of equal total protein lysates (input) and JAM-A immunoprecipitates (IP:JAM-A) from MCF7 cells
transfected with control siRNA or JAM-A-siRNA. (d) Western blot analysis of JAM-A, total Rap1, and active Rap1 protein expression in MCF7 cells
transfected with control or JAM-A siRNA and in MCF7 cells treated with isotype control antibody or JAM-A inhibitory antibody. (e) Densitometric
analysis of triplicate JAM experiments showing the ratio of active to total Rap1 after JAM-A knockdown or antagonism. Error bars refer to
standard deviation of triplicate experiments. JAM-A, junctional adhesion molecule-A.
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total protein expression of Rap1 following JAM-A
knockdown. However, a near abolition of active (GTP-
bound) Rap1 was observed in JAM-A knockdown cells.
In an effort to further confirm the regulation of Rap1
activation status by JAM-A, MCF7 cells were treated
with an inhibitory antibody to JAM-A (J10.4). Western
blot analysis demonstrated negligible changes in total
Rap1 expression but dramatic reductions in active Rap1
following JAM-A inhibition. Indeed, reductions of 50%
(P <0.01) and 80% (P <0.02) were observed for expres-
sion ratios of active Rap1 to total Rap1 following JAM-
A knockdown and inhibition, respectively (Figure 2e),
strongly indicating that JAM-A regulates downstream
activation of Rap1. However, it is notable that the ratios
of active-to-total Rap1 were not equivalent between
knockdown and inhibition conditions, because JAM-A
knockdown (but not inhibition) induced a reduction in
the total levels of Rap1 protein.
Inhibition of putative JAM-A signalling proteins reduces
breast cancer cell migration
Our results thus far suggested the existence of a JAM-A
signalling pathway in MCF7 breast cancer cells, and
that this pathway is initiated by JAM-A signalling via
Rap1 and b1-integrin and culminates in cancer cell
migration. We next reasoned that, if this pathway were
linear, inhibition of any step should elicit inhibitory
effects on cell migration similar to those induced upon
inhibition of JAM-A alone. To investigate this hypoth-
esis, we first treated MCF7 cells with the Rap1 pharma-
cological inhibitor GGTI-298 and verified that active
Rap1 is reduced following treatment (Figure 3a). GGTI-
298 also significantly reduced MCF7 cancer cell migra-
tion in scratch-wound assays (Figure 3b) (P = 0.015).
Next, we demonstrated that treatment of MCF7 cells
with an inhibitory antibody targeting b1-integrin elicited
a similar reduction in MCF7 cell migration, from
approximately 32% wound closure to 18% wound clo-
sure at 6 hours (Figure 3c) (P = 0.001). This was mir-
rored upon JAM-A inhibition, in which cell migration
was observed to decrease from approximately 32% to
15% wound closure after 6 hours (Figure 3d)
(P <0.0001). Combined treatment of MCF7 cells with
inhibitors of Rap1, b1-integrin, and JAM-A resulted in a
decrease in cancer cell migration from approximately
35% to 18% wound closure after 6 hours (Figure 3e)
(P <0.0001). When the migratory differences between
treatments and controls were quantitatively compared,
no additive effects in response to inhibitor combinations
versus single inhibitors alone were observed (Figure 3f).
This indicated that JAM-A, Rap1, and b1-integrin are
likely to function together in a linear signalling pathway
in breast cancer cells.
JAM-A co-associates with AF-6 and PDZ-GEF2
Using IP strategies, we next sought to determine the
JAM-A associations and signalling events that may affect
downstream Rap1 activation. Total protein was extracted
from MCF7 cells transfected with control siRNA or JAM-
A siRNA, and JAM-A protein-binding partners were co-
immunoprecipitated using an anti-JAM-A antibody
(Figure 4). We first tested for the presence of Rap1 in
JAM-A immunoprecipitates but did not detect any co-
association. We therefore reasoned that intermediate
signalling proteins must link JAM-A to the downstream
activation of Rap1. Knockdown of the Rap1-associating
protein [34] AF-6 (afadin) had been shown to result in
reductions in active Rap1 and colorectal cancer cell migra-
tion [27]. We therefore investigated whether JAM-A co-
associated with AF-6 in MC7F breast cancer cells. JAM-A
immunoprecipitates from MCF7 protein lysates were
immunoblotted with AF-6, and co-association between a
pool of JAM-A and AF-6 was detected (Figure 4). Similar
effects were observed using a second, independent JAM-A
siRNA construct (Supplementary Figure S1B in Additional
file 1). In addition to demonstrating a role for AF-6, pre-
vious studies had demonstrated a role for the Rap1 activa-
tor PDZ-GEF2 in both lung cancer cell adhesion [35] and
colorectal carcinoma cell migration [27]. Similarly, JAM-A
immunoprecipitates immunoblotted for PDZ-GEF2 con-
firmed co-association between a pool of JAM-A and PDZ-
GEF2 in MCF7 breast cancer cells (Figure 4).
JAM-A signalling complexes are altered in tissues of
patients with breast cancer
Our accumulating results suggested a breast cancer sig-
nalling pathway in which JAM-A associates with AF-6
and PDZ-GEF2 to activate Rap1 and regulate b1-integ-
rin-mediated cell migration. To determine the ex vivo
relevance of this putative JAM-A signalling pathway, we
sought to verify our results in primary cultures isolated
from multiple tissues of patients with breast cancer
(Table 1). Primary cultures were generated from three
patient-matched tumor (1T, 2T, and 3T) and non-
tumor (1N, 2N, and 3N) tissues, and total protein was
extracted for investigation of JAM-A co-associations.
JAM-A IP was conducted on all samples followed by
immunoblotting for JAM-A, AF-6, PDZ-GEF2, total
Rap1, and b1-integrin (Figure 5a). Analysis of total pro-
tein levels demonstrated a small increase in JAM-A
expression in patient tumor cultures relative to non-
tumor cultures (Figure 5a input and Supplementary Fig-
ure S3 in Additional file 3). Negligible differences in
protein expression between tumor and non-tumor cul-
tures were observed for AF-6, Rap1, and b1-integrin
(Figure 5a input and Supplementary Figure S3 in Addi-
tional file 3). Notably, however, after densitometric pool-
ing, tumor cultures displayed a reduced total protein
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cultures (Supplementary Figure S3 in Additional file 3).
Analysis of JAM-A immunoprecipitates demonstrated
co-association between JAM-A and a pool of AF-6 and
PDZ-GEF2 but not Rap1 or b1-integrin (Figure 5a),
which mirrors data acquired from MCF7 breast cancer
cells (Figure 4). Pooled densitometric analysis of tumor-
to-non-tumor ratios following IP experiments revealed a
trend toward increased association of both AF-6 and
PDZ-GEF2 with JAM-A, suggesting enhanced formation
of a JAM-A/AF-6/PDZ-GEF2 signalling complex in
tumor cells (Supplementary Figure S3 in Additional file
3). Together, our findings provide compelling evidence
of a novel role for the cell-cell adhesion protein, JAM-
A, in influencing breast cancer cell migration at the cell-
matrix interface via regulation of Rap1 and b1-integrin.
Discussion
Although recent improvements in breast cancer treat-
ments have resulted in average 10-year survival rates of
Figure 3 Rap1 or b1-integrin protein antagonism reduces breast cancer cell migration. (a) Western blot analysis of active Rap1 protein
expression in MCF7 cells following treatment with the Rap1 pharmacological inhibitor GGTI-298 (10 μM). Migration of MCF7 cells in scratch-
wound assays after pretreatment for 2 hours with Rap1 inhibitor (b), MAb 13 anti-b1-integrin inhibitory antibody (c), J104 anti-JAM-A inhibitory
antibody (d), or a combination of all three antagonists (e). Error bars refer to standard deviation and represent triplicate values in a
representative experiment. (f) Graphic representation of migration differences between control treatments and inhibitor/antibody treatments
alone and in combination. Error bars refer to standard deviation in pooled triplicate experiments. JAM-A, junctional adhesion molecule-A.
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Page 8 of 14approximately 72% [36], improved therapeutic strategies
are required to target metastasis, the leading cause of
death in patients with breast cancer. Loss of cell polarity
is an early indicator of carcinoma progression [2]. To
date, several proteins in cell polarity complexes [7,37]
and cell junctional complexes [38,39] have been impli-
cated in breast cancer [40]. Our previous studies
demonstrated a novel and significant association
between mammary overexpression of the TJ protein
JAM-A and poor prognosis of patients with breast can-
cer [19]. This was initially surprising in light of another
study reporting that loss of JAM-A promoted invasive
behavior in breast cancer cell lines [18,19]. However,
JAM-A likely plays a complex temporal role in cancer.
Low JAM-A expression could potentially reduce adhe-
sion and facilitate detachment of cells from early-stage
tumors; later on, signalling events arising from high
JAM-A expression may promote the migratory events
associated with tumor invasion and metastasis. Accord-
ingly, we demonstrated a link between JAM-A and b1-
integrin protein expression and a regulatory influence of
JAM-A on breast cancer cell migration in vitro [19].
The aim of the present study was to further elucidate
the mechanisms whereby JAM-A influences cancer cell
migration, in an attempt to explain the increased meta-
static events observed in breast cancer patients whose
tumors express high levels of JAM-A.
As presented in this article, our evidence is consistent
with a pathway whereby JAM-A regulates b1-integrin-
mediated breast cancer cell migration in vitro via altera-
tions in key signalling proteins downstream of JAM-A.
We have also verified that key JAM-related signalling
complexes exist ex vivo in primary cultures isolated
from tissues of patients with breast cancer, supporting
the clinical relevance of our studies.
W ef i r s td e m o n s t r a t e dt h a tk n o c k d o w no fJ A M - A
protein expression in MCF7 breast cancer cells signifi-
cantly reduced breast cancer cell adhesion and migra-
tion. These results are not surprising, given the
well-established functions of JAM-A in promoting
epithelial cell spreading [10] and leukocyte migration
[12]. However, it is important to note that JAM-A knock-
down or antagonism did not abolish cell migration, indi-
cating that this is not the sole regulatory pathway
controlling a process as fundamental as cell migration.
As the integrin family of proteins are crucial regula-
tors of both cell adhesion and cell migration [41], we
probed a putative cross-regulation between JAM-A and
integrins in breast cancer by measuring the expression
levels of several alpha- and beta-subunit integrins in
JAM-A knockdown MCF7 cells. Transient JAM-A
knockdown specifically reduced the expression of b1-
integrin and its alpha-subunit-binding partners aVa n d
a5. Integrin knockdown was predictably not absolute,
since integrins form the terminal step of migratory sig-
nalling cascades from multiple upstream regulators
[42,43]. Nonetheless, our results suggested that JAM-A
specifically affected b1-integrin heterodimers. Further-
more, previous studies had widely validated both aVb1
and a5b1 integrins as functioning fibronectin receptors,
thereby influencing our choices of substrate for migra-
tion and adhesion experiments [32]. Other evidence has
shown that both avb1a n da5b1 integrins are RGD-
binding integrins that recognize specific ligands contain-
ing an RGD tripeptide active site [32]. RGD-binding
integrins bind to several ligands (both extracellular
matrix and soluble), suggesting mechanisms to explain
the influence of integrins on diverse cellular processes.
Our results thus built upon studies in intestinal epithe-
lial cells [10,27] to show that JAM-A may regulate b1-
integrin-mediated migratory processes in breast cancer
cells. This is consistent with our previous work suggest-
ing a correlation between protein overexpression of
JAM-A and b1-integrin in breast cancer both in vivo
and in vitro [19]. Interestingly, the related family mem-
ber JAM-C has also been shown to exert regulatory
influence over b1-integrin activation and cell adhesion/
migration via a motif in the JAM-C cytoplasmic tail
[44].
b1-integrin has long been implicated in breast mor-
phogenesis [45] and malignancy [46] via its regulatory
influence on processes such as growth, apoptosis, migra-
tion, and invasion [20,47]. Indeed, inhibition of b1-integ-
rin in three-dimensional breast cell cultures in vitro has
been shown to phenotypically revert malignant cell
Figure 4 JAM-A co-associates with AF-6 and PDZ-GEF2 in
breast cancer cells. Immunoblot (IB) analysis for JAM-A, Rap1, AF-6,
and PDZ-GEF2 in equivalent concentrations of total protein lysates
(input) and JAM-A immunoprecipitates (IP:JAM-A) from mock-
transfected MCF7 cells and MCF7 cells transfected with control
short interfering RNA (siRNA) or JAM-A-siRNA. JAM-A, junctional
adhesion molecule-A.
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in vivo [48]. Expression of b1-integrin in human breast
cancer has been associated with poor patient survival
[23] and resistance to both radiotherapy [49] and the
adjuvant chemotherapy, trastuzumab (Herceptin) [50].
Given the pro-tumorigenic cellular processes governed
by b1-integrin signalling and given the effect of JAM-A
expression on b1-integrin protein expression, it was
logical to hypothesize that JAM-A may directly regulate
downstream b1-integrin-mediated processes.
To test this, we sought to determine whether JAM-A
signalling culminates in b1-integrin activation in breast
cancer cells. Our IP results showed no direct physical
co-association between these two proteins. However,
similar to studies in colonic epithelial cells [27], we
found that JAM-A knockdown or inhibition in breast
cancer cells significantly reduced the activity of Rap1
GTPase, a known activator of b1-integrins [24] and a
regulator of cellular adhesion [51]. Some residual Rap1
activity was observed even in JAM-A knockdown or
antagonized cells, consistent with the fact that there are
multiple known upstream regulators of Rap1 function
[51].
Rap1 GTPase protein activity is controlled by Rap
guanine nucleotide exchange factors (GEFs) and Rap
GTPase activating proteins (GAPs), which regulate gua-
nine nucleotide exchange and the thus activity status of
the protein [51]. Interestingly, increased Rap1 activity
Figure 5 JAM-A signalling is increased in breast cancer primary tumor cells. (a) Immunoblot analysis for JAM-A, AF-6, PDZ-GEF2, Rap1, and
b1-integrin protein expression conducted on input lysates of equivalent protein concentrations (left) and JAM-A immunoprecipitates (right)
isolated from matched tumor (T) and non-tumor (N) primary breast cultures. (b) Comparison of tumor-to-non-tumor ratios from pooled samples
of input protein and JAM-A immunoprecipitates for JAM-A, AF-6, and PDZ-GEF2 individually. JAM-A, junctional adhesion molecule-A.
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thyroid [52] and prostate [53]. Downregulation of Rap1
GAP, a negative regulator of Rap1 activity, has been
demonstrated in both pancreatic [54] and thyroid [52]
cancer. Furthermore, activation of Rap1 in prostate can-
cer cells increases cell migration and invasion in vitro,
and introduction of activated Rap1 in a xenograft pros-
tate cancer mouse model has been reported to enhance
metastasis [53]. To date, only one study (using mouse
xenograft models and three-dimensional cell culture
models) detailing the role of Rap1 in breast cancer has
been published [25]. The study demonstrated that Rap1
is a regulator of breast architecture, that normal levels
of activation maintain polarity during morphogenesis,
and that increased activation induces tumor formation
and breast cancer progression in vivo. Several studies
have investigated Rap activity via Rap GAP loss or Rap
GEF gain, but to our knowledge, none has focused on
the role of possible upstream effector proteins such as
JAM-A in breast cancer. However, it has been shown
independently that both JAM-A [55] and Rap1 [56] pro-
teins are required for fibroblast growth factor (FGF)-
induced angiogenesis in vitro.O u rr e s u l t sp r o v i d e
further evidence that Rap1 may represent an important
downstream effector of JAM-A in the development and
progression of breast cancer. That JAM-A, Rap1, and
b1-integrin exist in a linear pathway was supported by
evidence from migration assays in which combined
pharmacological inhibition of all three proteins failed to
exert additive effects relative to single inhibition of any
one protein.
To further probe the association of JAM-A and Rap1
in breast cancer, IP experiments were conducted to
identify direct binding partners that might physically
link both proteins. Like the authors of a previous study
[27], we were unable to detect direct co-association
between JAM-A and Rap1. However, JAM-A co-associa-
tions were detected with both the adhesion protein AF-
6 and the Rap GEF, PDZ-GEF2. AF-6 largely functions
to connect membrane-associated proteins to the actin
cytoskeleton [34] and is known to recruit and bind
JAM-A at intercellular junctions via a PDZ domain [57].
AF-6 has also been suggested to be a Rap effector [58],
and AF-6 knockdown in colonic epithelial cells report-
edly decreases Rap1 activity and cell migration in vitro
[27]. However, knockdown of AF-6 in T cells has been
shown to enhance Rap1-induced integrin-mediated cell
adhesion [34]. These contrasting roles for AF-6 are per-
haps not surprising when one considers that mainte-
nance of cell adhesion is crucial for epithelial cell
polarity but that maintenance of a non-adherent state is
favored for resting T-cell function. However, possible
mechanisms accounting for this duality are still
unknown. Little is known regarding the role of AF-6 in
breast cancer, and only a single study, owing to an
observed correlation between AF-6 loss and poor patient
prognosis, suggests AF-6 as a potential tumor suppres-
sor [59].
As mentioned above, GEF proteins such as PDZ-GEF2
are crucial activators of Rap1 GTPase [51]. Indeed, stu-
dies in colonic epithelial cells have demonstrated that
knockdown of PDZ-GEF2 simultaneously reduces b1-
integrin protein expression and cell migration [27].
Although there are no data regarding its expression or
dysregulation in breast cancer, PDZ-GEF2 has been
identified as an upstream activator of Rap1 required for
the maturation of adherens junctions in lung carcinoma
cells [35]. Given that dynamic adhesion changes are
involved in migration and invasion, it is plausible that
PDZ-GEF2 may also regulate these processes, which are
critical for cancer progression.
In this study, we have presented results indicating a
role for JAM-A in the regulation of b1-integrin-
mediated migratory processes in breast cancer cells.
Our data suggest a linear signalling pathway whereby
JAM-A engagement leads to activation of Rap1 via
PDZ-GEF2 and AF-6 and culminates in b1-integrin-
induced cell migration. These results are similar to
those from studies using colonic epithelial cells [27],
indicating that this JAM-A signalling pathway may be
conserved in several cell types. However, site-specific
expression of JAM-A in mouse endothelial cells has
been reported to prevent spontaneous motility in vivo
[60], illustrating that the in vivo role of JAM-A in regu-
lating migration is complex and spatially dependent. To
exclude the possibility of an artefactual JAM-Rap-b1-
integrin pathway in MCF7 cells, however, we have also
verified our results in primary breast cell cultures iso-
lated from tissues of patients with breast cancer. Our
data revealed an increase in JAM-A protein expression
in patient tumor cultures compared with non-tumor
cultures, corroborating our previous study observing
JAM-A overexpression in invasive breast cancer tissue
microarrays [19]. Patient primary cultures also showed
physical co-associations between JAM-A AF-6 and
PDZ-GEF2 but not with Rap1 or b1-integrin. This mir-
rors in vitro cell line data from us and others [27] and
further supports the possibility that JAM-A drives a
pro-migratory pathway.
Intriguingly, patient tumor primary cultures dis-
played a trend toward increased co-association of
JAM-A with both AF-6 and PDZ-GEF2 in comparison
with that in non-tumor cultures. This suggests the
potential for increased signalling via an AF-6/PDZ-
GEF2 pathway downstream of JAM-A overexpression
in tumor cells. We speculate that this could lead to
hyperactivation of Rap1 and consequent hyperactiva-
tion of b1-integrin (Figure 6). However, given the
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finite lifespan and slower growth and thus lower cell
numbers in comparison with immortalized cultures), it
was not feasible to conduct functional assays investi-
gating integrin-mediated cell migration or invasion
secondary to JAM-A protein manipulation. Future
work (including animal models) will shed further light
upon the mechanistic pathways involved in JAM-A sig-
nalling in vivo. Nonetheless, our current study has pre-
sented a model of JAM-A signalling in breast cancer
cells and may help to explain the increase in metastatic
events observed in breast cancer patients overexpres-
sing JAM-A [19].
Conclusions
Our findings provide compelling evidence of a novel
role for the cell-cell adhesion protein JAM-A in influ-
encing breast cancer cell migration. We have shown
that JAM-A signals via Rap1 and b1-integrin proteins,
both of which are crucial for cell adhesion, migration,
and invasion. Furthermore, when taken in context with
our previous study linking JAM-A and breast cancer,
our in vitro data from cell lines and patient primary
cultures suggest that JAM-A signalling may facilitate
metastatic spread. In fact, a recent article has identified
a micro-RNA (miR-145) whose overexpression reduces
invasive and motile behavior in breast cancer cells by
targeting JAM-A for downregulation [61]. We propose
that JAM-A-mediated ‘hijacking’ of adhesive and
migratory functions may represent a new therapeutic
target for the development of anti-migratory cancer
therapies.
Additional material
Additional file 1: Supplementary Figure S1. Reduced cell migration
downstream of JAM-A knockdown is reproducible with different
siRNA constructs. (A) Fold change in % wound closure over time of
control MCF7 cells compared with cells transfected with two separate
JAM-A siRNAs or a mock control siRNA. (B) Representative immunoblots
illustrating expression levels of JAM-A, AF-6, and Rap1 (left panel) or co-
precipitation of the same proteins with JAM-A (right panel) in MCF7 cells
transfected with two separate JAM-A siRNAs or a mock control siRNA.
Additional file 2: Supplementary Figure S2. JAM-A inhibition
reduces migration but not invasion of MCF7 cancer cells. (A)
Comparison of the relative invasion rates of MDA-MB-231, Hs579T cells
and MCF7 cells across Matrigel-coated Transwell filters; confirming the
non-invasive nature of MCF7 cells. Accordingly, although JAM-A
antagonism with the inhibitory antibody J10.4 exerted a significant anti-
migratory effect on MCF7 cells in scratch wound assays by 4 h (B),n o
significant antagonism of MCF7 invasion across Matrigel-coated filters
was observed even after 24 h exposure to J10.4 (C).
Additional file 3: Supplementary Figure S3. Pooled analysis of JAM-
A signalling proteins in tumour versus normal breast tissue primary
cultures. (A) Ratio of pooled tumor to non-tumor densitometric values
from JAM-A, AF-6, PDZ-GEF2, Rap1 and b1-integrin protein immunoblots
with equal total input protein concentrations. (B) Ratio of pooled tumor
to non-tumor densitometric values from JAM-A, AF-6, PDZ-GEF2, Rap1
and b1-integrin protein immunoblots of JAM-A immmunoprecipitates.
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